Benzinga - Feed Your Mind.

Market Overview

FDA

Tuesday, April 09, 2013

ARIAD Presents New Preclinical Data Showing Ponatinib Overcomes Resistant Mutations in KIT, an Oncogenic Driver of Gastrointestinal Stromal Tumors (ARIA, News, FDA / Tue, 08:01am)

Friday, March 22, 2013

UPDATE: ARIAD Confirms Positive CHMP Opinion for Iclusig Approval in EU (ARIA, News, FDA / Fri, 08:35am)

Friday, December 14, 2012

ARIAD Confirms Accelerated FDA Approval of Iclusig (ARIA, News, FDA / Fri, 01:57pm)

Tuesday, December 11, 2012

ARIAD Offers 12-Mo. Data from Pivotal PACE Trial of Ponatinib (ARIA, News, FDA / Tue, 09:12am)

Wednesday, November 28, 2012

ARIAD Pharma Publishes Phase 1 Trial Results of Ponatinib in NEJoM (ARIA, News, FDA / Wed, 06:02pm)

Thursday, September 27, 2012

ARIAD Completes Rolling Submission of New Drug Application for Ponatinib to the U.S. Food and Drug Administration (ARIA, News, FDA / Thu, 04:06pm)

Tuesday, September 18, 2012

MolecularMD Withdraws Premarketing Approval Application from FDA for its BCR-ABL T315I Mutation Test (ARIA, News, FDA / Tue, 07:39am)

Monday, July 30, 2012

Ariad Announces Submission of New Drug Application for Ponatinib to the U.S. Food and Drug Administration (ARIA, News, FDA / Mon, 04:09pm)

Friday, July 27, 2012

ARIAD Announces Initiation of Randomized Phase 3 Trial of Ponatinib in Newly Diagnosed Patients with Chronic Myeloid Leukemia (ARIA, News, FDA / Fri, 07:36am)

Monday, June 04, 2012

ARIAD Announces Updated Data from Pivotal PACE Trial of Ponatinib (ARIA, News, FDA / Mon, 07:04am)

Wednesday, March 21, 2012

Morning Social Media Outlook for Wednesday March 21 (SABA, KKD, TRGT, ARIA) (AAPL, AMZN, ARIA, BAC, Earnings, GS, KKD, Long Ideas, News, ORCL, SABA, TRGT, Guidance, Short Ideas, FDA, Movers, Tech, Trading Ideas / Wed, 11:13am)
UPDATE: Merck and ARIAD Pharmaceuticals Provide Update on FDA Advisory Committee Vote; Voted 13 To 1 Against The Use of Ridaforolimus (ARIA, MRK, News, FDA / Wed, 07:52am)

Wednesday, February 15, 2012

ARIAD Announces Issuance of Key U.S. Patent on Ponatinib (ARIA, News, FDA / Wed, 08:35am)

Monday, December 12, 2011

ARIAD Announces Preliminary Data from Pivotal Pace Trial of Ponatinib, Its Investigational pan-BCR-ABL Inhibitor (ARIA, News, FDA / Mon, 07:57am)

Friday, November 18, 2011

FDA Approves Erwinaze To Treat A Form Of Leukemia (ARIA, BMY, GSK, IBB, News, FDA / Fri, 10:34am)

Thursday, November 17, 2011

ARIAD Announces Interim Safety and Efficacy Data from Pivotal Ponatinib PACE Trial to Be Presented (ARIA, News, FDA / Thu, 08:36am)

Wednesday, October 05, 2011

FDA Accepts New Drug Application Filing for Ridaforolimus, Investigational mTOR Inhibitor (ARIA, MRK, News, FDA / Wed, 07:35am)

Monday, September 26, 2011

ARIAD Announces Long-Term Follow Up of Patients with Drug-Resistant CML Treated with Ponatinib in Phase 1 Trial (ARIA, News, FDA / Mon, 07:35am)

Wednesday, September 21, 2011

ARIAD Announces Start of Enrollment in Phase 1/2 Clinical Trial of Oral AP26113, an Investigational Dual Inhibitor of ALK and EGFR in Patients with Lung Cancer (ARIA, News, FDA / Wed, 07:36am)

Thursday, August 18, 2011

Merck and ARIAD Announce European Medicines Agency Accepts Marketing Authorization Application for Ridaforolimus (ARIA, MRK, News, FDA / Thu, 07:32am)

Monday, August 01, 2011

Monday, June 06, 2011

Merck and ARIAD Announce Presentation of Results of Phase III SUCCEED Trial at American Society of Clinical Oncology Annual Meeting (ARIA, MRK, News, FDA / Mon, 07:31am)

Friday, June 03, 2011

ARIAD Announces Initial Clinical Data on Ponatinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (ARIA, News, FDA / Fri, 07:36am)

Wednesday, April 20, 2011

REGENX BioSciences Licenses ARGENT Gene Regulation Technology From ARIAD Pharmaceuticals, Inc. (ARIA, News, FDA / Wed, 07:57am)
ARIAD Announces Three Exclusive Out-License Agreements to Develop and Commercialize Its ARGENT Cell-Signaling Regulation Technology (ARIA, News, FDA / Wed, 07:37am)

Tuesday, April 05, 2011

ARIAD Presents New Preclinical Data on Ponatinib in Solid Tumors, Demonstrating Inhibition of All FGF Receptor Kinases (ARIA, News, FDA / Tue, 07:36am)

Monday, March 28, 2011

ARIAD And MolecularMD Announce Collaboration for a Companion Diagnostic Test for The T315I BCR-ABL Mutation in Patients With CML (ARIA, News, FDA / Mon, 07:40am)

Benzinga Professional

08:06 PM Ebix, Goldman Sachs Affiliate to Terminate Merger Agreement
08:05 PM 'Hemlock Grove' to Return for Second Season on Netflix
08:03 PM Repros Therapeutics Prices 3.75M Share Offering at $19.00/Share
08:01 PM Kayne Anderson Increases Distribution to $0.58/Share for Q2 2013
08:01 PM CVB Financial Increases Q2 2013 Dividend 18%
07:08 PM Finisar Beats Estimates; Provides Q1 Guidance Above Consensus (FNSR)
07:06 PM Red Hat Jumps on Q1 Results (RHT)
07:05 PM Micron Reports Q3 Results Ahead of Estimates (MU)
07:03 PM Jabil Circuit Posts Lower Q3 Profit (JBL)
06:17 PM Benzinga's M&A Chatter for Wednesday June 19, 2013
5:40 PM Red Hat, Inc. Sees Q2 EPS $0.32-0.33 vs $0.33 Est; Sees Sales $370.0M-373.0M vs $373.20M Est
5:31 PM S&P Lowers Outlook on DISH to Negative
5:24 PM Form 8-K Filing from Depomed Shows FDA Web Site Indicates ANDA for Generic Zipsor Submitted, Says Zipsor Protected by Five Patents
5:22 PM Fulton Financial Files Mixed Securities Shelf
5:16 PM Whitestone REIT May Offer Up to $50M Shares

Brain Trust

Stocks to Watch for the Week of June 17, 2013

InvestorsObserver

MORE FROM InvestorsObserver

Myerson's Misses the Miasma that is Modern Executive Compensation

William K. Black

MORE FROM William K. Black

Rising Rates Destroys Refinances But Not Sales Yet

Logan Mohtashami

MORE FROM Logan Mohtashami

See All Brain Trust Columnists

stats for benzinga